ID22625A - Modifikasi kristal baru dari cdch, suatu proses untuk preparatnya dan formulasi farmasi terdiri dari modifikasi - Google Patents

Modifikasi kristal baru dari cdch, suatu proses untuk preparatnya dan formulasi farmasi terdiri dari modifikasi

Info

Publication number
ID22625A
ID22625A IDP963684A ID963684A ID22625A ID 22625 A ID22625 A ID 22625A ID P963684 A IDP963684 A ID P963684A ID 963684 A ID963684 A ID 963684A ID 22625 A ID22625 A ID 22625A
Authority
ID
Indonesia
Prior art keywords
modification
cdch
preparation
formulation containing
new crystals
Prior art date
Application number
IDP963684A
Other languages
English (en)
Indonesian (id)
Inventor
Alfons Dr Grunenberg
Patrick Dr Bosche
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7779831&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID22625(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of ID22625A publication Critical patent/ID22625A/id

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IDP963684A 1995-12-12 1996-12-10 Modifikasi kristal baru dari cdch, suatu proses untuk preparatnya dan formulasi farmasi terdiri dari modifikasi ID22625A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19546249A DE19546249A1 (de) 1995-12-12 1995-12-12 Neue Kristallmodifikation des 1-Cyclopropyl-7-([S,S]-2,8-diazabicyclo[4,3,0]non-8-yl)-6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäure Hydrochlorid (CDCH), Verfahren zu dessen Herstellung und diese enthaltende pharmazeutische Zubereitungen

Publications (1)

Publication Number Publication Date
ID22625A true ID22625A (id) 1999-12-02

Family

ID=7779831

Family Applications (1)

Application Number Title Priority Date Filing Date
IDP963684A ID22625A (id) 1995-12-12 1996-12-10 Modifikasi kristal baru dari cdch, suatu proses untuk preparatnya dan formulasi farmasi terdiri dari modifikasi

Country Status (42)

Country Link
US (1) US5849752A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0780390B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP4104687B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100525146B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1061348C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR005009A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE221531T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU708006B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG (1) BG62258B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9605968A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2192418C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO4480105A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CU (1) CU22774A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ288657B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE19546249A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0780390T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EE (1) EE03474B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2179910T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP960558B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU226521B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ID (1) ID22625A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL119795A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN185805B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (1) MA24342A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY117492A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300109I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO306725B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ299905A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL184885B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT780390E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RO (1) RO119782B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2162468C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SA (1) SA96170492B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG47201A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI0780390T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK282805B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SV (1) SV1996000109A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TR (1) TR199600970A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW411340B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA35638C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
YU (1) YU49485B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA9610405B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1895233A (zh) * 1997-09-25 2007-01-17 拜尔公司 控释活性化合物的药物制剂
DE19751948A1 (de) 1997-11-24 1999-05-27 Bayer Ag Verfahren zur Herstellung von 8-Methoxy-Chinoloncarbonsäuren
US6509327B1 (en) 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
US6716830B2 (en) 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
DK1128831T3 (da) 1998-11-10 2005-01-17 Bayer Healthcare Ag Farmaceutisk moxifloxacinpræparat
DE19854357A1 (de) * 1998-11-25 2000-05-31 Bayer Ag Semi-Hydrochlorid von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo/4.3.0/ -nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE19854356A1 (de) * 1998-11-25 2000-05-31 Bayer Ag Kristallmodifikation A von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo-/4.3.0/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE19854355A1 (de) * 1998-11-25 2000-05-31 Bayer Ag Kristallmodifikation B von 8-Cyan-1-cyclopropyl-7-(1S, 6S-2,8-diazabicyclo-/4.3.O/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE19908449A1 (de) * 1999-02-26 2000-08-31 Bayer Ag Kristallmodifikation C von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicylo-[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chino/incarbonsäure
EP1562942A1 (en) * 2002-10-31 2005-08-17 Ranbaxy Laboratories, Ltd. Amorphous moxifloxacin hydrochloride
EP2113505A1 (en) 2003-04-09 2009-11-04 Dr. Reddy's Laboratories, Ltd. A crystalline form III of anhydrous moxifloxacin hydrochloride and processes for the preparation thereof
EP1651630A1 (en) * 2003-08-05 2006-05-03 Matrix Laboratories Ltd An improved process for the preparation of moxifloxacin hydrochloride
WO2005054240A1 (en) * 2003-11-20 2005-06-16 Chemi Spa Polymorphs of 1-cyclopropyl-7-([s,s]-2,8-diazadicyclo[4.3.0]non-8-yl)-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinoline carboxylic acid hydrochloride and methods for the preparation thereof
ITMI20032259A1 (it) 2003-11-20 2005-05-21 Chemi Spa Nuovo polimorfo dell'acido 1-ciclopropil-7-(s,s-2,8-diazabciclo-4.3.0-non-8-il)-6-fluoro-1,4-diidro-8-metossi-4-oxo-chinolin carbossilico cloridrato e metodi per la sua preparazione
US7491725B2 (en) 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
DE102004015981A1 (de) * 2004-04-01 2005-10-20 Bayer Healthcare Ag Neue kirstalline Form von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE102004063347A1 (de) * 2004-12-23 2006-07-13 Stada Arzneimittel Ag Gebrauchsfertige Gemcitabinlösungen und Gemcitabinlösungskonzentrate
WO2007033515A1 (fr) * 2005-09-21 2007-03-29 Shenzhen Tys R & D Co., Ltd. Formulation orale contenant de la moxifloxacine et son procédé de préparation
GB0612422D0 (en) * 2006-06-23 2006-08-02 Generics Uk Ltd Novel hydrate form
CN101484411A (zh) 2006-06-27 2009-07-15 桑多斯股份公司 盐的新制备方法
ES2303768B1 (es) * 2006-09-08 2009-06-05 Quimica Sintetica, S.A. Nueva forma cristalina de moxifloxacino clorhidrato.
JP2010509305A (ja) * 2006-11-13 2010-03-25 シプラ・リミテッド モキシフロキサシン塩酸塩の合成方法
EP1992626A1 (en) * 2007-05-10 2008-11-19 Sandoz AG Process for the preparation of moxifloxacin hydrochloride
EP2083010A1 (en) * 2008-01-08 2009-07-29 Chemo Ibérica, S.A. Polymorphic Forms of Moxifloxacin hydrochloride and processes for preparation thereof
EP2154137A1 (en) 2008-08-04 2010-02-17 Chemo Ibérica, S.A. Crystalline form of moxifloxacin base
EP2349220B1 (en) 2008-10-09 2012-07-25 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Using of organic solvents in wet granulation of moxifloxacin
WO2010052726A1 (en) * 2008-11-06 2010-05-14 Hetero Research Foundation Novel polymorph of moxifloxacin hydrochloride
ES2467105T5 (es) 2008-12-08 2017-12-05 Ratiopharm Gmbh Moxifloxacino compactado
WO2010131054A1 (en) 2009-05-15 2010-11-18 Bradford Pharma Limited Redox drug derivatives
WO2011121596A2 (en) * 2010-04-01 2011-10-06 Neuland Laboratories Ltd. Crystal modification of moxifloxacin hydrochloride
BRPI1106900A2 (pt) 2011-12-26 2013-11-05 Ems Sa Composição farmacêutica sólida compreendendo antibótico da familia das quinolonas e processo de sua obtenção
FR2992218B1 (fr) 2012-06-22 2015-01-23 Rivopharm Sa Composition pharmaceutique de chlorhydrate de moxifloxacine et procede de preparation
CN102924449B (zh) * 2012-10-30 2015-08-12 重庆福安药业集团庆余堂制药有限公司 盐酸莫西沙星h晶型及其制备方法和药物组合物
EP2928892B1 (en) 2012-12-04 2018-03-21 Mankind Pharma Ltd. An improved process for the preparation of moxifloxacin hydrochloride
RU2561037C2 (ru) * 2013-02-07 2015-08-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Антибактериальная фармацевтическая композиция и способ ее получения
AU2014239965A1 (en) 2013-03-15 2015-09-24 Melinta Subsidiary Corp. Methods of treating infections in overweight and obese patients using antibiotics

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3601567A1 (de) * 1986-01-21 1987-07-23 Bayer Ag 7-(azabicycloalkyl)-chinoloncarbonsaeure- und -naphthyridon-carbonsaeure-derivate
DK164287A (da) * 1986-03-31 1987-10-01 Sankyo Co Quinolin-3-carboxylsyrederivater og fremgangsmaade til fremstilling deraf og deres anvendelse
AU609974B2 (en) * 1988-05-18 1991-05-09 Warner-Lambert Company Improved process for the preparation of 5-amino-7- (substituted amino)-quinoline-3-carboxylic acids
DE3910663A1 (de) * 1989-04-03 1990-10-04 Bayer Ag 5-alkylchinoloncarbonsaeuren
RO108347B1 (ro) * 1989-10-30 1994-04-28 Bellon Labor Sa Roger DERIVATI DE BENZO-(b)-NAFTIRIDIN-1,8 SI PROCEDEU DE PREPARARE A ACESTORA
TW209865B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1992-01-10 1993-07-21 Bayer Ag
CA2128601C (en) * 1992-01-31 2003-07-15 Hiroyuki Nagano Quinolone carboxylic acid derivatives in crystalline hydrate form
DE4234078A1 (de) * 1992-10-09 1994-04-14 Bayer Ag Chinoloncarbonsäuren
JP3268098B2 (ja) * 1992-12-25 2002-03-25 第一製薬株式会社 二環性環状アミン誘導体
ZA946853B (en) * 1993-09-10 1995-04-24 Daiichi Seiyaku Co Crystals of antimicrobial compound.
EP0676199B1 (en) * 1994-04-07 1998-09-02 Pfizer Inc. Use of trovafloxacin or derivatives thereof for the manufacture of a medicament for the treatment of H. pylori infections

Also Published As

Publication number Publication date
IL119795A0 (en) 1997-03-18
TR199600970A2 (tr) 1997-06-21
JP4104687B2 (ja) 2008-06-18
IN185805B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2001-05-05
SA96170492B1 (ar) 2006-05-23
US5849752A (en) 1998-12-15
RO119782B1 (ro) 2005-03-30
JPH09169757A (ja) 1997-06-30
EP0780390B1 (de) 2002-07-31
RU2162468C2 (ru) 2001-01-27
SG47201A1 (en) 1998-03-20
HRP960558A2 (en) 1998-02-28
DE59609501D1 (de) 2002-09-05
SI0780390T1 (en) 2002-10-31
BG62258B1 (bg) 1999-06-30
CA2192418A1 (en) 1997-06-13
AR005009A1 (es) 1999-04-07
HRP960558B1 (en) 2002-04-30
CZ288657B6 (cs) 2001-08-15
EE03474B1 (et) 2001-08-15
DK0780390T3 (da) 2002-11-11
EP0780390A1 (de) 1997-06-25
SV1996000109A (es) 1997-10-23
NL300109I1 (nl) 2003-02-03
PT780390E (pt) 2002-11-29
PL184885B1 (pl) 2003-01-31
BG101043A (en) 1998-04-30
BR9605968A (pt) 1998-08-18
CN1061348C (zh) 2001-01-31
EE9600201A (et) 1997-06-16
DE19546249A1 (de) 1997-06-19
NZ299905A (en) 1998-09-24
NO306725B1 (no) 1999-12-13
ZA9610405B (en) 1997-06-23
AU7421696A (en) 1997-06-19
ES2179910T3 (es) 2003-02-01
MY117492A (en) 2004-07-31
HUP9603428A2 (en) 1997-08-28
MX9606325A (es) 1997-10-31
HUP9603428A3 (en) 1997-10-28
YU65096A (sh) 1998-12-23
IL119795A (en) 1998-12-27
NO965298D0 (no) 1996-12-11
ATE221531T1 (de) 2002-08-15
HU9603428D0 (en) 1997-01-28
CU22774A3 (es) 2002-07-24
CN1160052A (zh) 1997-09-24
UA35638C2 (uk) 2001-04-16
AU708006B2 (en) 1999-07-29
HU226521B1 (en) 2009-03-30
MA24342A1 (fr) 1998-07-01
KR970042550A (ko) 1997-07-24
KR100525146B1 (ko) 2006-01-27
TW411340B (en) 2000-11-11
CA2192418C (en) 2001-06-12
CZ364696A3 (en) 1997-07-16
SK159196A3 (en) 1997-10-08
SK282805B6 (sk) 2002-12-03
CO4480105A1 (es) 1997-07-09
YU49485B (sh) 2006-08-17
PL317415A1 (en) 1997-06-23
NO965298L (no) 1997-06-13

Similar Documents

Publication Publication Date Title
ID22625A (id) Modifikasi kristal baru dari cdch, suatu proses untuk preparatnya dan formulasi farmasi terdiri dari modifikasi
BR9604894A (pt) Derivado de acetamida processo para a preparação do mesmo e uma composição farmacêutica contendo o mesmo
AU5471996A (en) Process for the preparation of microcapsule compositions
BR9600821A (pt) Composto formulação farmacêutica e processo para a preparação de um composto
FI973148L (fi) Substituoituja heterosyklisiä yhdisteitä, menetelmä niiden valmistamiseksi ja niitä sisältäviä farmaseuttisia koostumuksia
BR9609701A (pt) Composição farmacéutica composto e processo para a preparação de compostos
NO981150D0 (no) Konsentrert, flytende vaskemiddelblanding og fremgangsmåte for fremstilling av denne
NO981800D0 (no) FremgangsmÕte for fremstilling av 1,1,1,3,3-pentafluorpentan
ID25516A (id) Senyawa-senyawa yang mengandung cincin-cincin beranggotakan enam, proses pembuatannya, dan penggunaannya sebagai obat
ZA962916B (en) New arylglycineamide derivatives processes for the manufacture thereof and pharmaceutical compositions containing these compounds
NO944871D0 (no) Fremgangsmåte for fremstilling av polydimetylsiloksaner
AU6611396A (en) New oxazolidinone derivatives, processes for the production thereof and pharmaceutical agents containing these compounds
NO982237D0 (no) Ny fremgangsmÕte for fremstilling av fenylimidazolidinderivater
NO973460L (no) Fremgangsmåte for gjenvinning av kvikksölv
ID24173A (id) 1,2,3,4,5,6 heksahidro-2-6-metano-3-benzazosin-10-ol, proses pembuatan dan penggunannya untuk obat-obatan
ID20967A (id) Kroman tersubstitusi sulfonamida, proses pembuatannya, penggunaannya sebagai obat, dan sediaan farmasi yang mengandung bahan tersebut
NO961484D0 (no) Fremgangsmåte til undersökelse av silanbehandlede, uorganiske materialer
NO974155D0 (no) Ny fremgangsmåte for fremstilling av 2,3-dihydrobenzofuranolderivater
ID21873A (id) Turunan-turunan baru dari eritromisin, proses pembuatannya dan penggunaannya sebagai obat
NO960307D0 (no) Fremgangsmåte ved fremstilling av substituerte 4,6-diamino-5-cyanopyrimidiner
ID20968A (id) Kroman tersubstitusi sulfonamida, proses pembuatannya, penggunaannya sebagai obat, dan sediaan farmasi yang mengandung bahan tersebut
PT92345A (pt) Processo para a preparacao de composicoes farmaceuticas contendo derivados diterpenoides de labdano e derivados de pirimido(6,1-a)isoquinolina-4-ona
FI960587L (fi) Substituoituja bentseenisulfonyyliureoita, ja -tioureoita, menetelmä niiden valmistamiseksi ja niiden käyttö farmaseuttisen valmisteen valmistukseen sekä niitä sisältävät farmaseuttiset valmisteet
NO903347L (no) 14,17alfa-ethano- og ethanooestratriener, fremgangsmaate forfremstilling av disse forbindelser, saavel som anvendelse av dem for fremstilling av legemidler.
ID20718A (id) Senyawa tersubstitusi sulfonamida, proses pembuatannya, penggunaannya sebagai obat-obatan atau diagnostik, dan obat-obatan yang mengandung senyawa tersebut